Amrubicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Amrubicin
Accession Number
DB06263
Type
Small Molecule
Groups
Approved, Investigational
Description

Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of Amrubicin. [Press Release]

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Amrubicin hydrochlorideEUL6MP8FZW110311-30-3BHMLHEQFWVQAJS-IITOGVPQSA-N
International/Other Brands
Calsed
Categories
UNII
93N13LB4Z2
CAS number
110267-81-7
Weight
Average: 483.473
Monoisotopic: 483.152931389
Chemical Formula
C25H25NO9
InChI Key
VJZITPJGSQKZMX-XDPRQOKASA-N
InChI
InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
IUPAC Name
(7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy}-6,11-dihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
[H][[email protected]@]1(C[[email protected]@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[[email protected]]1C[[email protected]](O)[[email protected]](O)CO1

Pharmacology

Indication

Investigated for use/treatment in lung cancer.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

As an anthracycline, amrubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: amrubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

TargetActionsOrganism
UDNA topoisomerase 2-alphaNot AvailableHuman
UDNANot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Amrubicin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Amrubicin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumAmrubicin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidAmrubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Amrubicin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Amrubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
AmpicillinThe serum concentration of Amrubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Amrubicin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumAmrubicin may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylateAmrubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Amrubicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Amrubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Amrubicin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
BendazacBendazac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Amrubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
BevoniumBevonium may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
Botulinum Toxin Type AAmrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BAmrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amrubicin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amrubicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Amrubicin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Amrubicin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinAmrubicin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Amrubicin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
CisatracuriumAmrubicin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateAmrubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Amrubicin.Approved
Clodronic AcidAmrubicin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateAmrubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Amrubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
CyclosporineAmrubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Amrubicin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
DecamethoniumAmrubicin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Amrubicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Amrubicin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amrubicin.Approved, Investigational
Domoic AcidAmrubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideAmrubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Amrubicin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amrubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
Etidronic acidAmrubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Amrubicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Amrubicin.Approved, Vet Approved
GallamineAmrubicin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideAmrubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Amrubicin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
IbandronateAmrubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Amrubicin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
MecamylamineAmrubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Amrubicin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Amrubicin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Amrubicin.Experimental
MetocurineAmrubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideAmrubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Amrubicin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumAmrubicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Amrubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinAmrubicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Amrubicin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Amrubicin which could result in a higher serum level.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Amrubicin.Approved
OxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amrubicin.Approved, Vet Approved
PamidronateAmrubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumAmrubicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Amrubicin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Amrubicin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosidePeruvoside may decrease the cardiotoxic activities of Amrubicin.Experimental
PhenoxymethylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
PipecuroniumAmrubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Amrubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Amrubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Amrubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Amrubicin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Amrubicin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Amrubicin.Experimental
PTC299PTC299 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
PyrantelAmrubicin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumAmrubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateAmrubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumAmrubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
SuccinylcholineAmrubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Amrubicin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Amrubicin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Amrubicin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Amrubicin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateAmrubicin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateAmrubicin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Amrubicin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Amrubicin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidAmrubicin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amrubicin.Approved
TranilastTranilast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
TubocurarineAmrubicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Amrubicin.Approved
VecuroniumAmrubicin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidAmrubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

General References
  1. Katou M, Soga N, Onishi T, Arima K, Sugimura Y: Small cell carcinoma of the prostate treated with amrubicin. Int J Clin Oncol. 2008 Apr;13(2):169-72. doi: 10.1007/s10147-007-0702-x. Epub 2008 May 8. [PubMed:18463964]
  2. Kurata T, Okamoto I, Tamura K, Fukuoka M: Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs. 2007 Oct;25(5):499-504. Epub 2007 Jul 13. [PubMed:17628745]
External Links
PubChem Compound
3035016
PubChem Substance
347827767
ChemSpider
2299344
ChEBI
135779
ChEMBL
CHEMBL1186894
Wikipedia
Amrubicin
ATC Codes
L01DB10 — Amrubicin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentLung Cancers2
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingNot AvailableAdvanced thymic carcinoma / Thymic Carcinoma / Thymus Cancer1
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)3
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentSmall Cell Lung Cancer Extensive Stage1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentMetastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentLung Cancers1
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentLung Cancers1
3TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.14 mg/mLALOGPS
logP1.4ALOGPS
logP1.74ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)8.1ChemAxon
pKa (Strongest Basic)7.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area176.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity122.01 m3·mol-1ChemAxon
Polarizability48.75 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetracenequinones. These are polyaromatic hydrocarbon derivatives containing a tetracyclic cycle made up of four linearly fused benzene rings, one of which bears two ketone groups at position 1 and 4.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthacenes
Sub Class
Tetracenequinones
Direct Parent
Tetracenequinones
Alternative Parents
Anthraquinones / O-glycosyl compounds / Tetralins / Aryl ketones / Aralkylamines / Oxanes / Vinylogous acids / Alpha-amino ketones / Secondary alcohols / 1,2-diols
show 6 more
Substituents
Tetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Glycosyl compound / O-glycosyl compound / Tetralin / Aryl ketone / Aralkylamine / Oxane
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Kurata T, Okamoto I, Tamura K, Fukuoka M: Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs. 2007 Oct;25(5):499-504. Epub 2007 Jul 13. [PubMed:17628745]
2. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Unknown
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da

Drug created on March 19, 2008 10:20 / Updated on November 09, 2017 03:53